HC Wainwright Has Bullish Estimate for BCRX Q3 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Research analysts at HC Wainwright upped their Q3 2026 earnings per share (EPS) estimates for shares of BioCryst Pharmaceuticals in a report released on Thursday, August 6th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings of $0.15 per share for the quarter, up from their previous estimate of $0.05. HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($2.25) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ FY2026 earnings at ($2.12) EPS, FY2027 earnings at $0.89 EPS, FY2028 earnings at $1.33 EPS, FY2029 earnings at $2.00 EPS and FY2030 earnings at $3.20 EPS.

Other equities research analysts also recently issued research reports about the company. Wall Street Zen raised BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 8th. Citizens Jmp upped their price target on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 7th. Needham & Company LLC cut their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. JPMorgan Chase & Co. initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Monday, July 13th. They issued a “neutral” rating and a $12.00 price objective for the company. Finally, Cantor Fitzgerald boosted their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Tuesday, June 30th. Eight analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.60.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock opened at $9.70 on Monday. The business’s fifty day moving average price is $9.55 and its 200 day moving average price is $8.88. BioCryst Pharmaceuticals has a 1-year low of $6.00 and a 1-year high of $11.22. The firm has a market capitalization of $2.48 billion, a PE ratio of -6.47 and a beta of 0.56.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The business had revenue of $218.25 million during the quarter, compared to analysts’ expectations of $183.28 million. During the same period last year, the firm earned $0.15 EPS. The company’s quarterly revenue was up 33.6% compared to the same quarter last year.

Institutional Trading of BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Royal Bank of Canada increased its stake in shares of BioCryst Pharmaceuticals by 2.4% during the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 1,458 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in BioCryst Pharmaceuticals by 6.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock valued at $1,019,000 after buying an additional 8,517 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in BioCryst Pharmaceuticals by 49.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock valued at $14,490,000 after buying an additional 640,704 shares during the last quarter. Caxton Associates LLP acquired a new stake in BioCryst Pharmaceuticals during the 1st quarter valued at $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in BioCryst Pharmaceuticals by 11.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock valued at $3,363,000 after buying an additional 47,355 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.